Hepatocellular carcinoma resistance to tyrosine kinase inhibitors: Current status and perspectives  

作　　者：Yu-Run Miao Xiao-Jun Yang 

机构地区：[1]The First Clinical Medical School,Gansu University of Chinese Medicine,Lanzhou 730000,Gansu Province,China [2]Second Ward of General Surgery,Gansu Province People Hospital,Lanzhou 730000,Gansu Province,China

出　　处：《World Journal of Gastrointestinal Oncology》2025年第4期535-540,共6页世界胃肠肿瘤学杂志(英文)

基　　金：Supported by The National Health Commission's Key Laboratory of Gastrointestinal Tumor Diagnosis and Treatment for the Year 2022,National Health Commission's Master's and Doctoral/Postdoctoral Fund Project,No.NHCDP2022001;Gansu Provincial People's Hospital Doctoral Supervisor Training Project,No.22GSSYA-3.

摘　　要：The study conducted by Wang et al,focuses on the role of Rho GTPase activating protein 12(ARHGAP12),in hepatocellular carcinoma(HCC).This research reveals that ARHGAP12 expression,markedly elevated in malignant cells of HCC,correlates strongly with adverse outcomes for patients.Furthermore,the study illustrates that ARHGAP12 enhances the ability of HCC cells to invade and contributes to their resistance to tyrosine kinase inhibitors(TKIs)through modulation of the focal adhesion pathway.To comprehensively investigate the relationship between ARHGAP12 and TKI resistance,this study integrates single-cell and bulk RNA sequencing methodologies along with data from tumor immune single-cell hub 2,Gene Expression Omnibus,The Cancer Genome Atlas,CellMiner,Genomics of Drug Sensitivity in Cancer 2,as well as immunohisto-chemical staining and proteomic analyses.Statistical analyses,including the Wilcoxon rank-sum test and receiver operating characteristic curve analysis,were employed to evaluate the correlation between ARHGAP12 expression levels and clinical parameters,as well as drug sensitivity.It is evident that a more profound exploration of the molecular dynamics of HCC,especially those related to re-sistance against TKIs,is essential.

关 键 词：Tyrosine kinase inhibitor Hepatocellular carcinoma RESISTANCE Cancer therapy Rho GTPase activating protein 12 

分 类 号：R73[医药卫生—肿瘤]